Onco-Innovations Ltd. ( (TSE:ONCO) ) has shared an update.
Onco-Innovations Limited announced that its second-generation nanoparticle formulation of Polynucleotide Kinase 3′-Phosphatase (PNKP) Compound, when used in combination with radiation therapy, demonstrated a low toxicity profile in a study conducted by the University of Alberta. This finding is significant as it suggests the potential for developing safer and more effective cancer treatments with fewer side effects, providing a solid foundation for future research and reinforcing the company’s strong safety profile in advancing cancer therapies.
More about Onco-Innovations Ltd.
Onco-Innovations Limited is a Canadian-based company specializing in oncology, focusing on cancer research and treatment. The company aims to prevent and cure cancer through pioneering research and innovative solutions. Onco-Innovations holds an exclusive worldwide license to patented technology targeting solid tumors, striving to set new standards in cancer treatment and improve patient outcomes.
YTD Price Performance: 110.59%
Average Trading Volume: 470,647
Find detailed analytics on ONCO stock on TipRanks’ Stock Analysis page.